CELG: Celgene Corporation Elects James J. Loughlin to Board of Directors

Celgene Corporation (Nasdaq: CELG) announced the election of James J. Loughlin to the Company's Board of Directors. Mr. Loughlin is an experienced corporate director with a distinguished 40-year career with one of the world's leading professional accounting and business consulting firms where he reached the highest levels of corporate management and governance from entry level in 1964 to National Director of the Pharmaceuticals Practice, including a five-year term as member of the Board of Directors of KPMG LLP.

Mr. Loughlin served as chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. As Partner, Mr. Loughlin led multinational audits of pharmaceutical and financial services companies. Mr. Loughlin also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees.

"Celgene will benefit substantially from Jim's extensive financial and business consulting expertise," said Sol. J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene Corporation. "He is a welcomed addition to the Board and we look forward to his valuable contributions."